Daewoong Pharma
KRX:069620
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
100 600
161 100
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Daewoong Pharma
Daewoong Pharma
Net Income (Common)
Daewoong Pharma
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Daewoong Pharma
KRX:069620
|
Net Income (Common)
₩103.6B
|
CAGR 3-Years
108%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
13%
|
|
|
Yuhan Corp
KRX:000100
|
Net Income (Common)
₩165.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
31%
|
CAGR 10-Years
6%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Net Income (Common)
-₩32.9B
|
CAGR 3-Years
49%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Net Income (Common)
₩184.4B
|
CAGR 3-Years
100%
|
CAGR 5-Years
40%
|
CAGR 10-Years
15%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Net Income (Common)
₩5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-6%
|
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Net Income (Common)
₩16.5B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
81%
|
CAGR 10-Years
16%
|
|
Daewoong Pharma
Glance View
Daewoong Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceuticals. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2002-11-01. The firm's products mainly include antihypertensive drugs, antianemic agents, antidiabetic agents, antiemetic agents, antihistamine agents, antimicrobials, antineoplastics, antiobesity agents, antipyretic agents, analgesic agents, anti-inflammatory agents, biosimilars, remedies for bone and joint diseases, cardiovascular treatments, central nervous system treatments, digestive agents, dermatologic agents, gastrointestinal agents, health supplements and respiratory remedies, among others. The firm distributes its products in domestic and overseas markets.
See Also
What is Daewoong Pharma's Net Income (Common)?
Net Income (Common)
103.6B
KRW
Based on the financial report for Sep 30, 2024, Daewoong Pharma's Net Income (Common) amounts to 103.6B KRW.
What is Daewoong Pharma's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
13%
Over the last year, the Net Income (Common) growth was 123%. The average annual Net Income (Common) growth rates for Daewoong Pharma have been 108% over the past three years , and 13% over the past ten years .
You don't have any saved screeners yet
